The effect of Control IQ™ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis related diabetes

Author(s):  
Kevin J Scully ◽  
Gurunanthan Palani ◽  
Hui Zheng ◽  
Amir Moheet ◽  
Melissa S Putman
Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1065-P ◽  
Author(s):  
ANASTASIOS KOUTSOVASILIS ◽  
ALEXIOS SOTIROPOULOS ◽  
ANASTASIA ANTONIOU ◽  
VASILIOS KORDINAS ◽  
DESPINA PAPADAKI ◽  
...  

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 102-LB
Author(s):  
ADRIAN E. PROIETTI ◽  
MARCIAL A. ANGÓS ◽  
ALEJANDRO DAIN ◽  
MARIELA I. ECHENIQUE ◽  
MARÍA L. KABAKIAN ◽  
...  

Nutrients ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 310
Author(s):  
Kevin J. Scully ◽  
Laura T. Jay ◽  
Steven Freedman ◽  
Gregory S. Sawicki ◽  
Ahmet Uluer ◽  
...  

Measures of body fat and lean mass may better predict important clinical outcomes in patients with cystic fibrosis (CF) than body mass index (BMI). Little is known about how diet quality and exercise may impact body composition in these patients. Dual X-ray absorptiometry (DXA) body composition, 24-h dietary recall, and physical activity were assessed in a cross-sectional analysis of 38 adolescents and adults with CF and 19 age-, race-, and gender-matched healthy volunteers. Compared with the healthy volunteers, participants with CF had a lower appendicular lean mass index (ALMI), despite no observed difference in BMI, and their diets consisted of higher glycemic index foods with a greater proportion of calories from fat and a lower proportion of calories from protein. In participants with CF, pulmonary function positively correlated with measures of lean mass, particularly ALMI, and negatively correlated with multiple measures of body fat after controlling for age, gender, and BMI. Higher physical activity levels were associated with greater ALMI and lower body fat. In conclusion, body composition measures, particularly ALMI, may better predict key clinical outcomes in individuals with CF than BMI. Future longitudinal studies analyzing the effect of dietary intake and exercise on body composition and CF-specific clinical outcomes are needed.


2018 ◽  
Vol 379 (6) ◽  
pp. 547-556 ◽  
Author(s):  
Lia Bally ◽  
Hood Thabit ◽  
Sara Hartnell ◽  
Eveline Andereggen ◽  
Yue Ruan ◽  
...  

2021 ◽  
Author(s):  
Coralie Amadou ◽  
Sylvia Franc ◽  
Pierre-Yves Benhamou ◽  
Sandrine Lablanche ◽  
Erik Huneker ◽  
...  

<b>OBJECTIVE </b> <p>To analyze safety and efficacy of the DBLG1 hybrid closed-loop artificial pancreas system in patients with Type 1 Diabetes in real life conditions. </p> <p> </p> <p><b>METHODS</b></p> <p>Following a one-week run-in period with usual pump, 25 patients were provided with the commercial DBLG1 system. We present the results of Time-in-Range and HbA1c over a 6-month period.</p> <p><b> </b></p> <p><b>RESULTS</b></p> <p>The mean (SD;range) age of patients was 43 years (13.8; 25-72). At baseline, mean HbA1c and TIR 70-180mg/dL were respectively 7.9% (0.93; 5.6- 8.5) [63mmol/mol (10; 38-69)] and 53% (16.4;21-85). One patient stopped using the system after 2 months. At 6-month, mean HbA1c decreased to 7.1% [54mmol/mol] (p<0.001) and TIR 70-180mg/dL increased to 69.7% (p<0.0001). TIR<70mg/dL decreased from 2.4 to 1.3% (p=0.03). TIR<54mg/dL decreased from 0.32 to 0.24% (p=0.42). No serious adverse event was reported during the study. </p> <p> </p> <p><b>CONCLUSION</b></p> <p>The DBLG1 System confirms its ability to significantly improve glycemic control in real life conditions, without serious adverse events. </p>


CHEST Journal ◽  
2003 ◽  
Vol 123 (1) ◽  
pp. 42-48 ◽  
Author(s):  
Lutz Goldbeck ◽  
Tim G. Schmitz ◽  
Gerhard Henrich ◽  
Peter Herschbach

Sign in / Sign up

Export Citation Format

Share Document